The BRI3BP Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma line HT29, engineered to disrupt the BRI3BP gene. This product provides a mixed population of cells with heterogeneous gene editing events at the BRI3BP locus, offering a robust loss-of-function model for studying the anti-apoptotic functions of BRI3BP in a tumorigenic epithelial context. The polyclonal format captures a spectrum of genetic modifications without clonal selection, enabling physiologically relevant analysis of BRI3BP-dependent processes.
The HT29 cell line was established from a human colorectal adenocarcinoma and is widely employed as a model for intestinal epithelial barrier function and colon cancer research. These cells retain key epithelial characteristics, including the ability to form polarized monolayers and express tight junction proteins, making them suitable for studies of epithelial integrity and response to inflammatory stimuli. HT29 cells exhibit moderate tumorigenicity and are commonly used to investigate apoptosis regulation, particularly in the context of death receptor signaling, as they possess functional TNF receptor machinery and downstream apoptotic components.
BRI3BP functions as an anti-apoptotic factor by directly interacting with the transmembrane protein BRI3 to inhibit caspase-8 activation following engagement of death receptors such as TNFR1. Mechanistically, upon TNF-alpha stimulation, the formation of the TNFR1-FADD-caspase-8 complex triggers the extrinsic apoptotic pathway; BRI3BP associates with BRI3 and suppresses caspase-8 cleavage, thereby blocking downstream effector caspase activation and apoptosis execution. This inhibition is counterbalanced by ER stress signals that can modulate BRI3BP expression, linking the unfolded protein response to cell survival decisions. Key pathway components include TNF, TNFR1, FADD, caspase-8, BRI3, and BRI3BP, with BRI3BP positioned as a critical regulator at the intersection of TNF signaling, the extrinsic apoptotic cascade, and ER stress responses.
In the HT29 colorectal cancer background, knockout of BRI3BP is anticipated to relieve its inhibitory constraint on caspase-8, thereby sensitizing these cells to TNF-alpha-induced apoptosis. This model holds particular significance for colorectal cancer research, as dysregulation of apoptotic pathways contributes to tumorigenesis and chemoresistance. By abrogating an endogenous anti-apoptotic brake, the BRI3BP knockout polyclonal population enables dissection of how colorectal carcinoma cells modulate death receptor signaling and evade cell death, providing a platform for examining tumor cell vulnerability and therapeutic sensitization strategies.
Researchers can exploit this knockout model to investigate apoptotic signaling dynamics, death receptor pathways, and colon cancer chemosensitivity. Representative applications include performing caspase-8 activity assays and Annexin V staining to quantify apoptosis induction upon TNF-alpha treatment, western blotting for cleaved caspases to confirm pathway activation, and cell viability assays to assess overall sensitivity. Co-immunoprecipitation experiments can verify the disruption of BRI3BP-BRI3 complexes. This product is suited for advancing studies in apoptosis regulation, cancer biology, and preclinical therapeutic screening. For additional technical information and support, please contact Ascent Research.
